Literature DB >> 9393526

Colorectal cancer: diagnostic potential of CT measurements of hepatic perfusion and implications for contrast enhancement protocols.

D A Leggett1, B B Kelley, I H Bunce, K A Miles.   

Abstract

PURPOSE: To assess changes in hepatic perfusion in patients with colorectal cancer with computed tomography (CT), diagnostic potential of CT perfusion measurements, and implications for design of contrast enhancement protocols.
MATERIALS AND METHODS: In 27 patients with colorectal cancer, arterial and portal perfusion were calculated from temporal changes in attenuation after intravenous administration of contrast material.
RESULTS: Arterial perfusion greater than 0.25 mL/min/mL was seen in nine (82%) of the 11 patients with overt metastases versus six (38%) of the 16 patients with no overt metastases (P < .05). Portal perfusion of 0.25 mL/min/mL or less was found in five (46%) of the patients with overt metastases versus three (19%) of the patients with no overt metastases. Follow-up imaging showed progressive metastatic disease in three patients, all of whom had decreased portal perfusion.
CONCLUSION: Increased arterial perfusion appears to be an indicator of liver metastases, whereas reduced portal perfusion may indicate progressive disease. Contrast enhancement protocols that are based on experience with normal livers may not be optimal for patients with metastases.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9393526     DOI: 10.1148/radiology.205.3.9393526

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  27 in total

1.  Use of computed tomography in the management of colorectal cancer.

Authors:  Cher Heng Tan; Revathy Iyer
Journal:  World J Radiol       Date:  2010-05-28

2.  Perfusion computed tomography evaluation of angiogenesis in liver cancer.

Authors:  Han Feng Yang; Yong Du; Jia Xiang Ni; Xiang Ping Zhou; Jin Dong Li; Qing Zhang; Xiao Xue Xu; Yang Li
Journal:  Eur Radiol       Date:  2010-02-24       Impact factor: 5.315

Review 3.  Clinical application of hepatic CT perfusion.

Authors:  Liang Zhong; Wen-Jing Wang; Jian-Rong Xu
Journal:  World J Gastroenterol       Date:  2009-02-28       Impact factor: 5.742

4.  Quantification of hepatic arterial and portal perfusion with dynamic computed tomography: comparison of maximum-slope and dual-input one-compartment model methods.

Authors:  Masaya Miyazaki; Yoshito Tsushima; Akiko Miyazaki; Bishnuhari Paudyal; Makoto Amanuma; Keigo Endo
Journal:  Jpn J Radiol       Date:  2009-05-03       Impact factor: 2.374

5.  Dynamic contrast-enhanced CT imaging of hepatocellular carcinoma in cirrhosis: feasibility of a prolonged dual-phase imaging protocol with tracer kinetics modeling.

Authors:  Tong San Koh; Choon Hua Thng; Septian Hartono; Puor Sherng Lee; Su Pin Choo; Donald Y H Poon; Han Chong Toh; Sotirios Bisdas
Journal:  Eur Radiol       Date:  2009-01-10       Impact factor: 5.315

6.  Focusing on delayed clearance for identifying small-sized metastatic lung tumors using synchrotron radiation angiography with a highly sensitive receiver.

Authors:  Hiromichi Ito; Shonosuke Matsushita; Kazuyuki Hyodo; Hideo Tsurushima; Yukio Sato; Yuzuru Sakakibara
Journal:  Gen Thorac Cardiovasc Surg       Date:  2014-06-11

Review 7.  Perfusion computed tomography in colorectal cancer: protocols, clinical applications and emerging trends.

Authors:  Guang-Yao Wu; Prasanna Ghimire
Journal:  World J Gastroenterol       Date:  2009-07-14       Impact factor: 5.742

Review 8.  Perfusion magnetic resonance imaging of the liver.

Authors:  Choon Hua Thng; Tong San Koh; David J Collins; Dow Mu Koh
Journal:  World J Gastroenterol       Date:  2010-04-07       Impact factor: 5.742

9.  Does the presence of distant and local malignancy alter parenchymal perfusion in apparently disease-free areas of the liver?

Authors:  Y Tsushima; M J Blomley; H Yokoyama; S Kusano; K Endo
Journal:  Dig Dis Sci       Date:  2001-10       Impact factor: 3.199

10.  The use of perfusion CT for the evaluation of therapy combining AZD2171 with gefitinib in cancer patients.

Authors:  Martijn R Meijerink; Hester van Cruijsen; Klaas Hoekman; Matthijs Kater; Cors van Schaik; Jan Hein T M van Waesberghe; Giuseppe Giaccone; Radu A Manoliu
Journal:  Eur Radiol       Date:  2006-10-27       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.